Reverse Transcriptase News and Research

RSS

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

An international study with nearly 900 patients co-infected with Human Immunodeficiency Virus (HIV) and hepatitis C virus (HCV) has shown that HCV can be treated effectively and safely, without compromising the patient’s HIV therapy.

29 Jul 2004

Researchers discover a mechanism that blocks replication of a retrovirus

A team of scientists led by University of Georgia researchers has discovered a naturally occurring mechanism that blocks a critical step late in retrovirus replication.

21 Jul 2004

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV in patients who had failed prior PI-containing regimens, according to information presented at the International AIDS Conference (IAC).

12 Jul 2004

Relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds

HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance.

29 Jun 2004

Risk of artery plaques increased by use of HIV drugs

An Italian study has provided evidence that HIV drugs called protease inhibitors may increase the risk of artery "plaques."

15 May 2004

IPM takes over Microbicide development to protect against sexual transmission of HIV

International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson. The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect women from infection with HIV. This agreement marks the first collaboration in the microbicide field between a major healthcare company and a public-private partnership such as IPM.

29 Mar 2004